Understand the source comparison
LL-37 COA: Analytical Method Comparison
HPLC Purity (Area %) Percentage of target peptide vs impurities by chromatographic separation ≥98% by area under curve Confirms synthesis completion and purification efficacy. Values below 95% indicate significant truncated sequences or side products Non-negot
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- HPLC Purity (Area %)
- Percentage of target peptide vs impurities by chromatographic separation
- ≥98% by area under curve
- Confirms synthesis completion and purification efficacy. Values below 95% indicate significant truncated sequences or side products
- Non-negotiable quality threshold; sub-98% material compromises reproducibility
- Mass Spectrometry (MALDI or ESI)
- Molecular weight confirmation to verify correct amino acid sequence
- 4493.3 Da ±0.5 Da
- Detects amino acid deletions, substitutions, or oxidation. Errors >1 Da indicate structural defects
- Single most definitive structural verification; variance >0.5 Da = reject batch
- Endotoxin (LAL Assay)
- Bacterial lipopolysaccharide contamination from synthesis or handling
- <1.0 EU/mg (in vitro); <0.1 EU/mg (in vivo)
- LPS activates TLR4 pathways LL-37 also modulates. Contamination confounds immune response data
- Critical for immune studies; absence of numeric LAL result = unverifiable quality
- Peptide Content (Quantitative Amino Acid Analysis)
- Actual peptide mass per vial vs label claim
- ≥95% of stated mass
- Accounts for counterion mass (acetate, TFA) and residual water. Prevents under-dosing in protocols
- Often omitted by low-grade suppliers; explains why '5mg' vials deliver inconsistent results